Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

WORX vs CAH vs MCK vs HCAT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
WORX
SCWorx Corp.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$202K
5Y Perf.-99.9%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.59B
5Y Perf.+252.7%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+413.8%
HCAT
Health Catalyst, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$113M
5Y Perf.-95.4%

WORX vs CAH vs MCK vs HCAT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
WORX logoWORX
CAH logoCAH
MCK logoMCK
HCAT logoHCAT
IndustryMedical - Healthcare Information ServicesMedical - DistributionMedical - DistributionMedical - Healthcare Information Services
Market Cap$202K$43.59B$92.15B$113M
Revenue (TTM)$3M$250.55B$403.43B$311M
Net Income (TTM)$-4M$1.56B$4.76B$-178M
Gross Margin32.0%3.7%3.6%48.7%
Operating Margin-33.3%0.9%1.5%-51.7%
Forward P/E17.9x19.3x14.1x
Total Debt$2K$9.35B$7.39B$20M
Cash & Equiv.$2M$3.87B$5.69B$51M

WORX vs CAH vs MCK vs HCATLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

WORX
CAH
MCK
HCAT
StockMay 20May 26Return
SCWorx Corp. (WORX)1000.1-99.9%
Cardinal Health, In… (CAH)100352.7+252.7%
McKesson Corporation (MCK)100513.8+413.8%
Health Catalyst, In… (HCAT)1004.6-95.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: WORX vs CAH vs MCK vs HCAT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CAH and MCK are tied at the top with 3 categories each — the right choice depends on your priorities. McKesson Corporation is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. HCAT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
WORX
SCWorx Corp.
The Defensive Pick

WORX is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.77, Low D/E 0.0%, current ratio 2.72x
Best for: sleep-well-at-night
CAH
Cardinal Health, Inc.
The Income Pick

CAH carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 20 yrs, beta 0.03, yield 1.1%
  • Beta 0.03, yield 1.1%, current ratio 0.94x
  • Beta 0.03 vs HCAT's 2.05
  • 1.1% yield, 20-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Best for: income & stability and defensive
MCK
McKesson Corporation
The Growth Play

MCK is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • 348.1% 10Y total return vs CAH's 160.8%
  • 16.2% revenue growth vs WORX's -3.7%
  • 1.2% margin vs WORX's -154.4%
Best for: growth exposure and long-term compounding
HCAT
Health Catalyst, Inc.
The Value Play

HCAT is the clearest fit if your priority is value.

  • Lower P/E (14.1x vs 17.9x)
Best for: value
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs WORX's -3.7%
ValueHCAT logoHCATLower P/E (14.1x vs 17.9x)
Quality / MarginsMCK logoMCK1.2% margin vs WORX's -154.4%
Stability / SafetyCAH logoCAHBeta 0.03 vs HCAT's 2.05
DividendsCAH logoCAH1.1% yield, 20-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Momentum (1Y)CAH logoCAH+22.0% vs WORX's -91.2%
Efficiency (ROA)MCK logoMCK5.7% ROA vs WORX's -61.6%, ROIC 5.4% vs -14.5%

WORX vs CAH vs MCK vs HCAT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

WORXSCWorx Corp.
FY 2017
Promotion Segment
71.7%$3M
Athlete Management
22.1%$934,043
Ticket Service Segment
5.2%$221,183
Corporate Segment
0.9%$36,330
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B
HCATHealth Catalyst, Inc.
FY 2025
Recurring Technology
100.0%$208M

WORX vs CAH vs MCK vs HCAT — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCAHLAGGINGHCAT

Income & Cash Flow (Last 12 Months)

Evenly matched — WORX and MCK each lead in 2 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 140195.3x WORX's $3M. MCK is the more profitable business, keeping 1.2% of every revenue dollar as net income compared to WORX's -154.4%. On growth, WORX holds the edge at +13.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricWORX logoWORXSCWorx Corp.CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HCAT logoHCATHealth Catalyst, …
RevenueTrailing 12 months$3M$250.5B$403.4B$311M
EBITDAEarnings before interest/tax$972,248$3.2B$6.8B-$110M
Net IncomeAfter-tax profit-$4M$1.6B$4.8B-$178M
Free Cash FlowCash after capex-$2M$4.4B$6.0B-$5M
Gross MarginGross profit ÷ Revenue+32.0%+3.7%+3.6%+48.7%
Operating MarginEBIT ÷ Revenue-33.3%+0.9%+1.5%-51.7%
Net MarginNet income ÷ Revenue-154.4%+0.6%+1.2%-57.2%
FCF MarginFCF ÷ Revenue-54.0%+1.8%+1.5%-1.5%
Rev. Growth (YoY)Latest quarter vs prior year+13.8%+11.0%+6.0%-6.2%
EPS Growth (YoY)Latest quarter vs prior year+63.6%-19.5%+37.0%-2.9%
Evenly matched — WORX and MCK each lead in 2 of 6 comparable metrics.

Valuation Metrics

Evenly matched — WORX and HCAT each lead in 2 of 6 comparable metrics.

At 28.7x trailing earnings, CAH trades at a 2% valuation discount to MCK's 29.2x P/E. On an enterprise value basis, CAH's 16.0x EV/EBITDA is more attractive than MCK's 18.7x.

MetricWORX logoWORXSCWorx Corp.CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HCAT logoHCATHealth Catalyst, …
Market CapShares × price$202,035$43.6B$92.1B$113M
Enterprise ValueMkt cap + debt − cash-$1M$49.1B$93.8B$82M
Trailing P/EPrice ÷ TTM EPS-0.08x28.72x29.25x-0.62x
Forward P/EPrice ÷ next-FY EPS est.17.94x19.28x14.15x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple16.01x18.74x
Price / SalesMarket cap ÷ Revenue0.07x0.20x0.26x0.36x
Price / BookPrice ÷ Book value/share0.05x0.45x
Price / FCFMarket cap ÷ FCF23.56x17.63x
Evenly matched — WORX and HCAT each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-73 for WORX. WORX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to HCAT's 0.08x. On the Piotroski fundamental quality scale (0–9), CAH scores 6/9 vs WORX's 4/9, reflecting solid financial health.

MetricWORX logoWORXSCWorx Corp.CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HCAT logoHCATHealth Catalyst, …
ROE (TTM)Return on equity-73.5%+3.0%-54.7%
ROA (TTM)Return on assets-61.6%+2.8%+5.7%-27.4%
ROICReturn on invested capital-14.5%+33.8%+5.4%-32.9%
ROCEReturn on capital employed-16.4%+19.2%+30.5%-34.0%
Piotroski ScoreFundamental quality 0–94666
Debt / EquityFinancial leverage0.00x0.08x
Net DebtTotal debt minus cash-$2M$5.5B$1.7B-$31M
Cash & Equiv.Liquid assets$2M$3.9B$5.7B$51M
Total DebtShort + long-term debt$1,539$9.3B$7.4B$20M
Interest CoverageEBIT ÷ Interest expense-0.49x6.38x33.79x-4.79x
MCK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — CAH and MCK each lead in 3 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $23 for WORX. Over the past 12 months, CAH leads with a +22.0% total return vs WORX's -91.2%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs WORX's -76.9% — a key indicator of consistent wealth creation.

MetricWORX logoWORXSCWorx Corp.CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HCAT logoHCATHealth Catalyst, …
YTD ReturnYear-to-date-75.8%-9.5%-8.5%-30.3%
1-Year ReturnPast 12 months-91.2%+22.0%+4.6%-59.9%
3-Year ReturnCumulative with dividends-98.8%+127.3%+106.4%-86.9%
5-Year ReturnCumulative with dividends-99.8%+235.7%+286.9%-97.0%
10-Year ReturnCumulative with dividends-100.0%+160.8%+348.1%-95.9%
CAGR (3Y)Annualised 3-year return-76.9%+31.5%+27.3%-49.2%
Evenly matched — CAH and MCK each lead in 3 of 6 comparable metrics.

Risk & Volatility

CAH leads this category, winning 2 of 2 comparable metrics.

CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than HCAT's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAH currently trades 79.3% from its 52-week high vs WORX's 5.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricWORX logoWORXSCWorx Corp.CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HCAT logoHCATHealth Catalyst, …
Beta (5Y)Sensitivity to S&P 5001.77x0.03x0.04x2.05x
52-Week HighHighest price in past year$13.05$233.60$999.00$5.06
52-Week LowLowest price in past year$0.20$137.75$637.00$0.96
% of 52W HighCurrent price vs 52-week peak+5.7%+79.3%+75.3%+31.4%
RSI (14)Momentum oscillator 0–10018.633.216.263.9
Avg Volume (50D)Average daily shares traded1.6M1.7M757K720K
CAH leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

CAH leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: CAH as "Buy", MCK as "Buy", HCAT as "Buy". Consensus price targets imply 57.2% upside for HCAT (target: $3) vs 33.8% for MCK (target: $1007). For income investors, CAH offers the higher dividend yield at 1.10% vs MCK's 0.36%.

MetricWORX logoWORXSCWorx Corp.CAH logoCAHCardinal Health, …MCK logoMCKMcKesson Corporat…HCAT logoHCATHealth Catalyst, …
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$249.67$1006.50$2.50
# AnalystsCovering analysts333122
Dividend YieldAnnual dividend ÷ price+1.1%+0.4%
Dividend StreakConsecutive years of raises22017
Dividend / ShareAnnual DPS$2.04$2.69
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.8%+3.4%+4.4%
CAH leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

CAH leads in 2 of 6 categories (Risk & Volatility, Analyst Outlook). MCK leads in 1 (Profitability & Efficiency). 3 tied.

Best OverallCardinal Health, Inc. (CAH)Leads 2 of 6 categories
Loading custom metrics...

WORX vs CAH vs MCK vs HCAT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is WORX or CAH or MCK or HCAT a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -3. 7% for SCWorx Corp. (WORX). Cardinal Health, Inc. (CAH) offers the better valuation at 28. 7x trailing P/E (17. 9x forward), making it the more compelling value choice. Analysts rate Cardinal Health, Inc. (CAH) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — WORX or CAH or MCK or HCAT?

On trailing P/E, Cardinal Health, Inc.

(CAH) is the cheapest at 28. 7x versus McKesson Corporation at 29. 2x. On forward P/E, Health Catalyst, Inc. is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — WORX or CAH or MCK or HCAT?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -99. 8% for SCWorx Corp. (WORX). Over 10 years, the gap is even starker: MCK returned +348. 1% versus WORX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — WORX or CAH or MCK or HCAT?

By beta (market sensitivity over 5 years), Cardinal Health, Inc.

(CAH) is the lower-risk stock at 0. 03β versus Health Catalyst, Inc. 's 2. 05β — meaning HCAT is approximately 5933% more volatile than CAH relative to the S&P 500. On balance sheet safety, SCWorx Corp. (WORX) carries a lower debt/equity ratio of 0% versus 8% for Health Catalyst, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — WORX or CAH or MCK or HCAT?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -3. 7% for SCWorx Corp. (WORX). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — WORX or CAH or MCK or HCAT?

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus -154. 4% for SCWorx Corp. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — HCAT leads at 48. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is WORX or CAH or MCK or HCAT more undervalued right now?

On forward earnings alone, Health Catalyst, Inc.

(HCAT) trades at 14. 1x forward P/E versus 19. 3x for McKesson Corporation — 5. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HCAT: 57. 2% to $2. 50.

08

Which pays a better dividend — WORX or CAH or MCK or HCAT?

In this comparison, CAH (1.

1% yield), MCK (0. 4% yield) pay a dividend. WORX, HCAT do not pay a meaningful dividend and should not be held primarily for income.

09

Is WORX or CAH or MCK or HCAT better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Health Catalyst, Inc. (HCAT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAH: +160. 8%, HCAT: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between WORX and CAH and MCK and HCAT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: WORX is a small-cap quality compounder stock; CAH is a mid-cap quality compounder stock; MCK is a mid-cap high-growth stock; HCAT is a small-cap quality compounder stock. CAH pays a dividend while WORX, MCK, HCAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

WORX

Quality Business

  • Sector: Healthcare
  • Market Cap > $20B
  • Revenue Growth > 6%
  • Gross Margin > 19%
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

HCAT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 29%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform WORX and CAH and MCK and HCAT on the metrics below

Revenue Growth>
%
(WORX: 13.8% · CAH: 11.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.